Holen Sie sich die Stockscreener-App
1.12
1.75%
-0.02
Handel nachbörslich:
1.11
-0.01
-0.89%
Tiziana Life Sciences Ltd Aktie (TLSA) Neueste Nachrichten
Market movers: HPE, Boeing, Salesforce, Tiziana Life Sciences... - Proactive financial news
Tiziana Life Sciences seeks FDA orphan drug status for nasal MSA therapy - Yahoo Finance
Tiziana Life Sciences Seeks FDA Orphan Status for Intranasal Foralumab in Multiple System Atrophy - TipRanks
Tiziana Life Sciences Files for Orphan Drug Designation with the FDA for Intranasal Foralumab for the Treatment of Multiple System Atrophy (MSA) - The Manila Times
Form 4 Tiziana Life Sciences Ltd For: 30 September By Investing.com - Investing.com Canada
Tiziana Life Sciences doses first ALS patients in Phase 2a Foralumab trial - Proactive financial news
Small cap wrap: M2i Global, Sigma Lithium, 1911 Gold, Tiziana Life Sciences... - Proactive financial news
Tiziana begins dosing ALS patients in Phase 2a trial of nasal antibody foralumab - Pluang
Tiziana Life Sciences Announces First Participants Dosed in ALS BANYAN Clinical Trial of Intranasal Foralumab - The Manila Times
Three people with ALS have received their first doses in a trial of a nasal drug. - Stock Titan
The ALS Association co-funds a nasal-treatment trial as Tiziana (TLSA) doses its first patients. - Stock Titan
Tiziana doses first three patients in ALS trial of nasal antibody foralumab - Proactive financial news
TLSA Reiterated by BTIG -- Price Target Maintained at $7.00 - GuruFocus
BTIG Maintains Tiziana Life Sciences(TLSA.US) With Buy Rating, Maintains Target Price $7 - Moomoo
Small cap wrap: Tiziana Life Sciences, First Phosphate, Ocean Power Technologies, Midnight Sun Mining... - Proactive financial news
Tiziana Life Sciences completes patient visits in Phase 2a MS drug trial - Yahoo Finance
Tiziana Life Sciences to Announce Topline Data From Phase 2a Na-SPMS Trial in October - marketscreener.com
Tiziana Life Sciences (TLSA) Completes Phase 2a Trial, Faces Val - GuruFocus
Tiziana Life Sciences Completes Last Patient Visit in Phase 2a INFORM-MS Trial - TipRanks
Tiziana Life Sciences announces last patient completed Phase 2a INFORM-MS trial - TipRanks
Tiziana Life Sciences Announces Last Patient Last Visit in Phase 2a INFORM-MS Trial of Intranasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis - Quiver Quantitative
The last patient has finished an MS drug trial. Early results are expected in October. - Stock Titan
Last patient finishes Tiziana (TLSA) MS trial ahead of October data - Stock Titan
Tiziana Announces Last Patient Completes Last Visit in Phase 2a INFORM-MS Trial of Intranasal Foralumab - The Manila Times
Tiziana Life Sciences Ltd(NasdaqCM: TLSA) dropped from S&P Global BMI Index - marketscreener.com
Tiziana Life Sciences stock jumps on MS trial partnership - Investing.com
Tiziana (TLSA) Up +25.96% — Will the Rally Hold Through Earnings? 2026-09-17Combination Correction - siam.in
Why Is Tiziana Life Sciences Stock Gaining Thursday? - Benzinga
Tiziana Life Sciences (NASDAQ: TLSA) Enters MOU to Launch RRMS Combination Therapy Trial - kalkinemedia.com
Small cap wrap: Sigma Lithium, Tiziana Life Sciences, Gunnison Copper, Purepoint Uranium... - Proactive financial news
Tiziana Life Sciences partners with Saudi institutions on MS combination therapy trial - Yahoo Finance
Tiziana Life Sciences stock jumps on MS trial partnership By Investing.com - Investing.com Canada
Tiziana Life Sciences Signs Saudi Collaboration MOU for New Multiple Sclerosis Trial - TipRanks
Tiziana Life Sciences (TLSA) Advances MS Clinical Trial Collaboration Amid Challenging Valuation - GuruFocus
Tiziana Life Sciences signs MOU with KAIMRC in Saudi Arabia - TipRanks
Tiziana Life Sciences Signs MOU with KAIMRC and Foundation for Neurologic Diseases to Study Intranasal Foralumab in RRMS - Quiver Quantitative
Tiziana (TLSA) lines up MS trial for patients failing current drugs with a nasal antibody twist. - Stock Titan
Tiziana Life Sciences Announces Signing of Mo - Moomoo
A planned MS trial will test Tiziana’s nasal drug with existing treatment - Stock Titan
TLSA: Tiziana Life Sciences Ltd Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
BTIG Initiates Tiziana Life Sciences(TLSA.US) With Buy Rating, Announces Target Price $7 - Moomoo
Tiziana Life Sciences gets Buy rating from BTIG on Treg-based approach to neurodegeneration - Yahoo Finance
Small cap wrap: Tiziana Life Sciences, Thistle Resources, Alvopetro, BioHarvest... - Proactive financial news
Tiziana Life Sciences initiated with a Buy at BTIG - TipRanks
This Occidental Petroleum Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Benzinga
TLSA Initiated Coverage by BTIG -- Price Target Set at $7.00 - GuruFocus
BTIG Initiates Tiziana Life Sciences at Buy With $7 Price Target - marketscreener.com
BTIG initiates Tiziana Life Sciences stock with buy on MS drug - Investing.com India
Wall Street ends on a mixed note as Dow gains despite semiconductor slump - proactiveinvestors.com.au
Market movers: Strategy, Bitmine, Tiziana Life Sciences... - Proactive Investors
Tiziana (NASDAQ: TLSA) highlights intranasal ALS trial and MS data - Stock Titan
Tiziana Life Sciences Announces Poster Presentation on Phase 2a BANYAN Clinical Trial of Intranasal Foralumab at ALS Nexus 2026 - kommunikasjon.ntb.no
Tiziana Life Sciences Ltd (TLSA) Earnings Forecast: Future EPS & Revenue Growth Estimates - tradingkey.com
Tiziana Life Sciences (TLSA) insider adds 42,357 shares via Panetta Partners - Stock Titan
Tiziana Life Sciences Ltd (TLSA) director adds 15,000 shares in open-market buy - Stock Titan
Tiziana Life Sciences CEO & Executive Director Acquires 18% More Stock - simplywall.st
Tiziana Life Sciences (TLSA) CEO Boosts Stake Amid Unprofitable Operations and Low Valuation - GuruFocus
TLSA | Tiziana Life Sciences Ltd. Insider Trading - Quiver Quantitative
Insider Buying: Tiziana Life Sciences (NASDAQ:TLSA) CEO Purchases 83,807 Shares of Stock - marketbeat.com
Ivor Elrifi Acquires 237,616 Shares of Tiziana Life Sciences (NASDAQ:TLSA) Stock - marketbeat.com
Tiziana Life Sciences : Announces Purchase of Shares by Chief Executive Officer - marketscreener.com
Tiziana Life Sciences (Nasdaq: TLSA) CEO boosts stake with 321,423-share buy - Stock Titan
Tiziana Life Sciences announces CEO share purchase - Proactive financial news
Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer - The Manila Times
0.05%
0.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):